SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 4/30/15 Adaptimmune Therapeutics PLC 8-A12B 1:25K Merrill Corp-MD/FA |
Document/Exhibit Description Pages Size 1: 8-A12B Registration of a Class of Securities HTML 19K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-A
FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
PURSUANT TO SECTION 12(b) OR (g) OF THE
SECURITIES EXCHANGE ACT OF 1934
Adaptimmune Therapeutics plc
(Exact name of registrant as specified in its charter)
England and Wales |
|
N/A |
(State of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
91 Park Drive, Milton Park Abingdon, Oxfordshire OX14 4RY United Kingdom |
|
OX14 4RY |
(Address of principal executive offices) |
|
(Zip Code) |
Securities to be registered pursuant to Section 12(b) of the Act:
Title of each class to be so registered |
|
Name of each exchange on which each class is to be registered |
|
|
|
American Depositary Shares each representing six Ordinary Shares |
|
The NASDAQ Stock Market LLC |
|
|
|
Ordinary Shares, par value £0.001 per share |
|
The NASDAQ Stock Market LLC* |
If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c), check the following box. x
If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d), check the following box. o
Securities Act registration statement file number to which this form relates: 333-203267
Securities to be registered pursuant to Section 12(g) of the Act: None
* Application to be made for listing, not for trading, but only in connection with the registration of the American Depositary Shares pursuant to the requirements of the Securities and Exchange Commission.
Item 1. Description of Registrant’s Securities to be Registered
The description of the securities to be registered hereunder is contained in the sections entitled “Dividends and Dividend Policy,” “Description of Share Capital and Articles of Association,” “Description of American Depositary Shares,” “Ordinary Shares and ADSs Eligible For Future Sale” and “Taxation” of the prospectus included as part of the Registrant’s Registration Statement on Form F-1 (No. 333-203267), as amended, originally filed with the Securities and Exchange Commission on April 6, 2015 under the Securities Act of 1933, and is hereby incorporated by reference in answer to this Item.
Item 2. Exhibits
Pursuant to the Instructions as to Exhibits with respect to Form 8-A, no exhibits are required to be filed, because no other securities of the Registrant are registered on The NASDAQ Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.
Date: April 30, 2015 |
|
|
| |
|
ADAPTIMMUNE THERAPEUTICS PLC | |||
|
| |||
|
By: |
/s/ James J. Noble | ||
|
Name: |
|||
|
Title: |
Chief Executive Officer | ||
This ‘8-A12B’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 4/30/15 | |||
4/6/15 | F-1 | |||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/28/22 Adaptimmune Therapeutics plc 424B5 1:285K Toppan Merrill/FA 4/21/22 Adaptimmune Therapeutics plc S-3/A 1:671K Toppan Merrill/FA 4/08/22 Adaptimmune Therapeutics plc S-3 6:1.1M Toppan Merrill/FA 8/10/20 Adaptimmune Therapeutics plc S-3ASR 8/10/20 5:1.6M Toppan Merrill/FA |